United
States
Securities
and Exchange Commission
Washington,
DC 20549
Form
8-K
Current
Report
Pursuant
to Section 13 or 15(d) of
The
Securities Exchange Act of 1934
Date of
Report: December 30, 2010
GeneLink,
Inc.
(Exact
Name of Registrant as Specified in its Charter)
|
PA
|
00-30518
|
23-2795613
|
|
(State
or other
Jurisdiction
of
Incorporation)
|
(Commission
File Number)
|
(IRS
Employer Identification
No.)
|
317 Wekiva Springs Road,
#200, Longwood, FL 32779
(Address
of Principal Executive Offices)
Registrant’s
telephone number, including area code: (800)
558-4363
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
|
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
- 1
-
ITEM 5.02 DEPARTURE OF DIRECTORS OR
CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS;
COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS
|
(b)
|
Departure of Executive
Officers
|
On December 30, 2010, GeneLink, Inc.
(the “Company”) terminated the employment of Gary J. Beeman as Chief Executive
Officer President of the Company and terminated the employment of Michael J.
Nelson as Chief Operating Officer of the Company.
|
(c)
|
Appointment of Executive
Officer
|
Bernard L. Kasten, Jr., M.D. was
appointed the acting Chief
Executive Officer and President of the Company effective December 30, 2010.
Dr. Kasten, 64, has been a member of the Board of Directors of the
Company since 2007 and is the Executive Chairman of the Board of Directors of
the Company. Dr. Kasten has been a scientific advisor to the Company since 1999
and a member of the Company's Advisory Committee since 2001. Dr.
Kasten is a graduate of Miami University (Oxford Ohio), BA Chemistry 1967, and
the Ohio State University College of Medicine MD 1971. His residency was served
at the University of Miami, Florida and fellowships at the National Institutes
of Health Clinical Center and National Cancer Institute, Bethesda, Maryland. Dr.
Kasten is a Diplomat of the American Board of Pathology with Certification in
Anatomic and Clinical Pathology with sub-specialty certification in Medical
Microbiology. Dr. Kasten is an author of "Infectious Disease Handbook" 1st
through 5th Editions 1994-2003 and the "Laboratory Test Handbook" 1st through
4th Editions 1984-1996 published by Lexi-Comp Inc., Hudson, Ohio. Dr. Kasten has
been active with the College of American Pathologists (CAP) serving as Chairman
of its Publication Committee from 1985-1993, its Management Resources Committee
from 1993-1998 and its Chairman Internet Editorial Board from 1999-2003. Dr.
Kasten received the College of American Pathologists Presidents Medal Awarded
for Outstanding Service in 1989 and the College of American Pathologists Frank
W. Hartman Award, in 1993 for Meritorious Service to the College (Founding CAP
Today) the organization's highly successful monthly tabloid magazine. Dr.
Kasten's professional staff appointments have included the Cleveland Clinic,
Northeastern Ohio Universities College of Medicine, the Bethesda Hospitals and
Quest Diagnostics. Dr. Kasten served eight years, 1996-2004, at Quest
Diagnostics Incorporated [NYSE-DGX], where he was Chief Laboratory Officer;
Vice-President of Business Development for Science and Medicine and
Vice-President of Medical Affairs of a Quest Diagnostics wholly-owned
subsidiary, MedPlus Inc. Dr. Kasten joined SIGA Technologies, Inc. [NASDAQ-SIGA]
as a Board of Directors member in May 2003, and accepted the appointment as
SIGA's Chief Executive Officer in July of 2004, serving through April 2006. Dr.
Kasten is Chairman of the Board of Cleveland Bio Labs Inc. [NASDAQ-CBLI], and
also serves on the Board of Directors of CytoLogic Inc, Lexi-Comp Inc,
Riggs-Heinrich Media Inc and Enzo Biochem Inc. [NYSE-ENZ].
- 2
-
Signatures
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| GeneLink, Inc. | ||
| (Registrant) | ||
|
By:
|
/s/ Bernard L. Kasten,
Jr. M.D.
|
|
|
Bernard
L. Kasten, Jr. M.D.
|
||
|
Chief
Executive Officer
|
||
Dated:
January 3, 2011
- 3
-